Edward Nash
Stock Analyst at Canaccord Genuity
(4.22)
# 453
Out of 5,055 analysts
83
Total ratings
57.33%
Success rate
13.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $529.21 | +10.92% | 12 | Nov 13, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $106 → $107 | $39.11 | +173.59% | 2 | Nov 12, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $14 → $16 | $9.25 | +72.97% | 7 | Nov 7, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Hold | $73 → $54 | $54.25 | -0.46% | 7 | Oct 9, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $7.75 | +261.29% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $3.99 | +401.25% | 3 | Sep 30, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $140 | $75.51 | +85.41% | 10 | Sep 25, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $25.55 | +142.66% | 3 | Sep 17, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $34.50 | +36.23% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $1.88 | +378.72% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.68 | +138.10% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $65.50 | +35.88% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.02 | +684.31% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $9.87 | +72.24% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.33 | -14.16% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.04 | +17,207.69% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $33.08 | +147.88% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $4.29 | +1,764.80% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $29.88 | +60.64% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $4.45 | +14,506.74% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $529.21
Upside: +10.92%
Viking Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $39.11
Upside: +173.59%
Ventyx Biosciences
Nov 7, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $9.25
Upside: +72.97%
Akero Therapeutics
Oct 9, 2025
Downgrades: Hold
Price Target: $73 → $54
Current: $54.25
Upside: -0.46%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $7.75
Upside: +261.29%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $3.99
Upside: +401.25%
Corcept Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $140
Current: $75.51
Upside: +85.41%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $25.55
Upside: +142.66%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $34.50
Upside: +36.23%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.88
Upside: +378.72%
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.68
Upside: +138.10%
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $65.50
Upside: +35.88%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.02
Upside: +684.31%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $9.87
Upside: +72.24%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.33
Upside: -14.16%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.04
Upside: +17,207.69%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $33.08
Upside: +147.88%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $4.29
Upside: +1,764.80%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $29.88
Upside: +60.64%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $4.45
Upside: +14,506.74%